Clinical Trial Update: Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mesenchymal stromal cell therapy to prevent bronchopulmonary dysplasia in extreme preterm infants. The study is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia

Drugs mentioned

• Mesenchymal Stromal Cell Therapy

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Bronchopulmonary Dysplasia (BPD), ELGAN (22-28SA) | Phase 2 | Status: NOT_YET_RECRUITING